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The aim of this study was to find factors that could explain the accumulation difference of mitoxantrone in the BCRP1-negative
GLC4-MITO cell line compared to GLC4. Comparative genomic hybridisation (CGH) was applied to determine chromosomal
differences between GLC4 and GLC4-MITO. Comparative genomic hybridisation analysis revealed gain of 2q, 6p, 9q, 13q, 14q, 15q,
19q and Xp and loss of 1p, 2q, 3p, 3q, 4q, 6q, 8q, 11p, 16p, 17q, 18p, 20p and Xq. In the over-represented chromosomal areas, seven
transporter genes were identified: ABCB6, ABCB2 (TAP1), ABCB3 (TAP2), ABCF1 (ABC50), ABCC10 (MRP7), ABCA2 (ABC2)
and ABCC4 (MRP4). No RNA or protein upregulation was observed for ABCB6, ABCF1, ABCC10, ABCC4, ABCB2 and ABCB3,
but an increased expression was detected for ABCA2 mRNA in GLC4-MITO. ABCA2 is known to be involved in resistance to
estramustine. In the MTT assay, GLC4-MITO was two-fold resistant to estramustine compared to GLC4. Coincubation with
estramustine and mitoxantrone increased mitoxantrone accumulation in GLC4-MITO, while this was not affected in GLC4. This
suggests that estramustine is able to block mitoxantrone efflux in GLC4-MITO cells. These data reveal that cellular reduction of
mitoxantrone in a mitoxantrone-resistant cell line is associated with overexpression of ABCA2.
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The treatment of patients with anticancer agents is still seriously
hampered by the occurrence of resistance against standard
anticancer drugs and crossresistance to many other cytotoxic
agents. The ATP-binding cassette transporter (ABC) superfamily
has been implicated as a major contributor to the multidrug-
resistance phenotype (Klein et al, 1999). The most studied
members are the P-glycoprotein (P-gp) encoded by the MDR1
gene (Ambudkar et al, 1999) and the MDR-related protein (MRP)
family of the ABC protein transporters, especially the MRP1 gene
(Borst et al, 1999). Currently, 48 human ABC transporters are
known (Mu ¨ller M (2001). Transporters in the liver and ATPbinding
Casette (ABC)-Proteins October 2002 Internet communication,
http://nutrigene.4t.com/humanabc.htm). In addition, it has be-
come clear that often more than one mechanism is involved in
multidrug-resistance of tumor cells.
Resistance to the anticancer drug mitoxantrone has been
associated with several mechanisms including drug accumulation
defects and reduction in its target proteins topoisomerase IIa and
b (Withoff et al, 1996). Recently, overexpression of the breast
cancer-resistance half-transporter protein (BCRP1) was found to
be responsible for the occurrence of mitoxantrone resistance in a
number of cell lines (Doyle et al, 1998; Miyake et al, 1999; Ross
et al, 1999; Litman et al, 2000). However, not all mitoxantrone-
resistant cell lines express BCRP1 (Hazlehurst et al, 1999; Nielsen
et al, 2000). The efflux pump responsible for the mitoxantrone
resistance in these cell lines is as yet unknown. The mitoxantrone-
resistant GLC4 subline GLC4-MITO exhibits a reduced mitoxan-
trone accumulation (Withoff et al, 1996). Scheffer et al (2000)
had already shown that there was no BCRP1 protein expression
in GLC4-MITO using BXP-34 antibody . This suggests that a
different efflux pump may be involved in mitoxantrone resistance
in GLC4-MITO.
We used comparative genomic hybridisation (CGH) to deter-
mine chromosomal differences between the human small cell lung
cancer cell line (SCLC) GLC4 and its mitoxantrone-resistant
subline. Comparison of the cell lines showed gains of specific
chromosomal regions. Screening of several databases revealed
seven known efflux pumps located in the amplified regions. A
possible involvement of these pumps was analysed by reverse
transcriptase–polymerase chain reaction (RT–PCR) for mRNA
expression, cytotoxicity with the microculture tetrazolium assay
(MTA), drug accumulation by flow cytometry analysis and
immunocytochemistry for protein expression.
MATERIAL AND METHOD
Cell lines
For this study, we used two cell lines: GLC4, a drug-sensitive
human SCLC cell line and GLC4-MITO, a GLC4 subline with an in
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svitro induced mitoxantrone resistance (Zijlstra et al, 1986; Withoff
et al, 1996). GLC4-MITO was previously shown to exhibit a 60%
reduced topoisomerase IIa compared to GLC4 and no topoisome-
rase IIb RNA expression at all. In addition, a decreased
mitoxantrone accumulation was found. There was a 3.6-fold
crossresistance to doxorubicin without reduction in doxorubicin
accumulation (Withoff et al, 1996). Earlier studies detected no
overexpression or activation of P-gp, MRP1 (multidrug-resistant
protein) and LRP (lung-resistance protein) in the GLC4-MITO cell
line (Withoff et al, 1996). Both cell lines were cultured in RPMI
1640 supplemented with 10% heat-inactivated fetal calf serum,
(371C, 5% CO2). GLC4-MITO was incubated twice monthly with
285nM mitoxantrone to maintain the mitoxantrone resistance.
Before performing the experiments described below, cells were
cultured drug free for 14 days. Routinely mitoxantrone sensitivity
was checked by MTA every 3 months. A mean mitoxantrone-
resistance factor of 33-fold was established. For the RT–PCR
experiments, we used MCF7, a human breast carcinoma cell line
and MCF7-MX, its 1395-fold mitoxantrone-resistant subline with
increased BCRP1 mRNA expression compared to MCF7 (Ross et al,
1999; Volk et al, 2000) as controls. For the MTA experiments with
estramustine, we included GLC4-ADR, a 150-fold doxorubicin-
resistant GLC4 subline with increased MRP1 and LRP expression
but no reduced mitoxantrone accumulation (Zijlstra et al, 1987) as
a control.
Cytogenetics
The cell cultures were harvested and chromosome preparations
were made using standard cytogenetic techniques. The chromo-
somes were G-banded using 0.1% pancreatin (Sigma, Zwijndrecht,
the Netherlands) and 10% Giemsa. A total of 10 metaphases from
the GLC4 and the GLC4-MITO cell line were analysed. Karyotypes
were described according to the ISCN (1995). chromosomal
pattern of GLC4-MITO was compared with that of GLC4.
Comparative genomic hybridisation
Cells of subconfluent cultures were harvested and genomic
DNA was extracted according to standard methods. Compara-
tive genomic hybridisation was performed as described by
Kallioniemi et al (1992) with some adjustments. Approximately
1mg of test DNA and 1mg of reference DNA were labelled by
nick translation with either Biotin-16-dUTP or digoxigenin-
11-dUTP (Roche Molecular Biochemicals, Almere, Netherlands).
Aliquots of 400ng labelled test DNA and control DNA were
ethanol precipitated with 50mg unlabelled human Cot1 DNA (Life
Technologies, Breda, the Netherlands) and 10mg of salmon
sperm DNA (Sigma, Zwijndrecht, the Netherlands). The DNA
solution was dissolved in 15ml hybridisation mixture (50%
deionized formamide, 2 SSC, 10% dextran sulphate pH 7.0)
and applied to a normal male metaphase slide (Vysis, Downers
Grove, IL, USA). The slide with the DNA hybridisation solution
was denatured at 741C for 3min and hybridized at 371C for 72h.
Posthybridisation washes with 4 saline-sodium citrate (SSC),
3 0.1 SSC at 601C were performed before immunochemical
detection. Immunochemical detection was performed using
streptavidin-FITC (Roche Molecular Biochemicals) and anti-
DIG-TRITC (Roche Molecular Biochemicals, Almere, Netherlands)
in 4 SSC, Tween-20 and 1% fat-free powder milk during 1h
to detect the biotin-labelled tumour DNA and digoxigenin-labelled
normal DNA. The slides were mounted with antifading solu-
tion containing 4,6-diamidino-2-phenylindole (DAPI), used as
a counter stain (Vectashield, Vector laboratories, Burlingame,
CA, USA).
The grey-scale images of the three different fluorochromes were
captured using a Leica DMRA fluorescence microscope equipped
with DAPI, FITC and TRITC filters (Chroma, Brattleboro, VT,
USA), CCD camera (Cohu 4912 CCD camera, San Diego, CA, USA)
and the image-capturing program QFISH (Leica, Cambridge, UK).
The three captured images were combined and pseudocolor was
applied matching the original colours of the fluorochromes. The
ratio between the FITC (tumour cell line) and TRITC (normal)
fluorescence was calculated with use of the QCGH software
program (Leica, Cambridge). For each case, the mean of the
individual ratio profiles of 8–10 metaphase spreads was calculated.
The GLC4 and the GLC4-MITO cell line were compared with
normal DNA. In addition, we directly compared GLC4-MITO with
its parent line GLC4.
RNA extraction and RT–PCR
Total cellular RNA was isolated from 5 10
6 cells using 1ml
of Trizol reagent (Life Technologies, Breda, the Netherlands).
RNA was extracted, precipitated and washed according to the
manufacturer’s protocol. RNA (2mg) was reverse transcribed in
20ml of reverse transcriptase (RT) buffer (Life Technologies),
supplemented with 1.8mM dTTP (Promega Corp., Madison, WI,
USA), 10U of Moloney murine leukemia virus RT (Amersham-
Pharmacia, Woerden, The Netherlands), 4.8U RNAguard (Amer-
sham-Pharmacia, Woerden, The Netherlands), 0.2mg pd(N)6
random primers (Amersham-Pharmacia,) and 3mM dithiothreitol
(Life Technologies). The reaction conditions were 651C for 10min
and 371C for 60min. After this incubation, 30mlH 2O was added
up to a final volume of 50ml cDNA. Polymerase chain reac-
tion analysis was performed in 25ml PCR buffer containing 2ml
of cDNA using the primer pairs and conditions as described
in Table 1.
The PCR reaction product bands were visualised by ethidium
bromide staining. Densitometric scanning was performed with an
Image Master VDS (Pharmacia, Woerden, The Netherlands), and
optical density (OD) was expressed as OD mm
2 using the
program Diversity One 1D (PDI, New York, NY, USA).
Immunocytochemistry for ABCB2 (TAP1), ABCB3 (TAP2)
proteins
Cytospin slides were prepared from cultured GLC4 and GLC4-
MITO cells. The cytospins were fixed in acetone for 10min,
transferred to ice-cold methanol for 10min and washed with
phosphate-buffered saline (PBS), pH 7.4. The cytospins were
incubated for 1h at room temperature with the primary antibody
ABCB2 (TAP1), ABCB3 (TAP2) (antibodies kindly provided by Dr
J Neefjes, Dutch Cancer Institute, the Netherlands) diluted in 1%
bovine serum albumin in PBS. Endogenous peroxidase was
blocked with 0.3% H2O2 for 30min. For ABCB3 and ABCB2
antibodies, the second step was performed with peroxidase-
conjugated rabbit anti-mouse antibody (Dakopatts, Glosstrup,
Denmark) supplemented with 1% human serum, followed by
incubation with goat anti-rabbit antibody (Dakopatts). The
visualisation was performed in a freshly prepared solution of
3-amino-9-ethylcarbazol (AEC), containing 0.03% H2O2 for
10min. Counterstaining was performed using Mayer’s haematox-
ylin. Control slides, in which PBS replaced the first antibody, were
consistently negative.
Cytotoxicity assay
Cytotoxicity of estramustine was determined using MTA as
described before (Timmer-Bosscha et al, 1989). Before the assays
were performed, cell growth studies were carried out, and the
linear relationship of cell number to formazan crystal formation
was checked. Each cell line was seeded at optimum density in order
to test survival after at least two to three cell divisions had taken
place in the control cells. For GLC4, 3 10
4 cellsml
 1 and for
GLC4-ADR and GLC4-MITO, 7.5 10
4cells ml
 1 were incubated
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scontinuously for 4 days with estramustine concentrations ranging
from 1 to 100mM. Controls consisted of media without cells
(background extinction) and cells incubated in microculture wells
with medium without the drug. The surviving fraction was
calculated by the ratio of mean extinction of test sample to mean
extinction of untreated control sample. Inhibition concentration
(IC)50,I C 70 and IC90 were defined as the doses of estramustine
inducing 50, 70, and 90% reduction in cell survival, respectively.
Experiments were performed four times each in quadruplicate.
Flow cytometric detection of mitoxantrone accumulation
The ability of tumour cell lines GCL4 and GLC4-MITO to extrude
mitoxantrone in the absence or presence of the ABCA2 modulator
estramustine, the P-gp inhibitor PSC833 (provided by Novartis
Pharma Inc., Basel Switzerland), the BCRP1 inhibitor fumitremor-
gin C (FTC) (kindly provided by SE Bates) and the leukotriene D4
receptor antagonist and MRP inhibitor MK-571 (provided by
Sanvertech, Heerhugowaard, The Netherlands) was measured in a
fluorescence-activated cell sorting (FACS) assay (Van der Kolk
et al, 2002). Cells (1 10
6) were preincubated with these inhibitors
for 30min at 371C, 5% CO2, in the following combinations: RPMI
1640 medium alone (0.5ml), RPMI 1640 medium plus 10mM FTC,
or plus 2mgml
 1 PSC833 or plus 20mM MK-571. Thereafter, 3mM
mitoxantrone was added and the cells were incubated for 60min at
371C, 5% CO2.
Cells (1 10
6) were preincubated with and without 10 or 25mM
estramustine (modulator of ABCA2), 3mM mitoxantrone was
added and the cells were incubated for 60min at 371C, 5% CO2.
Cells were washed with ice-cold RPMI 1640 medium. Fluorescence
of mitoxantrone was analysed with a FACScalibur flow cytometer
(Becton Dickson Medical Systems, Sharon, MA, USA), equipped
with an argon laser. The viable cell population was gated by
forward and sideways scatter characteristics. The mitoxantrone
fluorescence of 10000-gated events was logarithmically measured
at a laser excitation wavelength of 635nm through a 670nm band-
pass filter. Mitoxantrone accumulation was expressed as median
fluorescence intensity (MFI). The effect of the various modulators
was expressed as a shift of MFI of the mitoxantrone accumulation
(Van der Kolk et al, 2002). Measurements were performed on
duplicate samples and experiments were performed in triplicate.
Statistics
For the statistical analysis of the data retrieved in the mitoxantrone
accumulation and cytoxicity experiments, we used the paired or
unpaired Student’s t-test.
RESULTS
Cytogenetics revealed a complex karyotype with marker chromo-
somes in both GLC4 and GLC4-MITO (data not shown).
Comparison of the CGH results with cytogenetics showed that
numerical differences detected with CGH were also observed in the
karyotypes of GLC4 and GLC4-MITO.
Comparative genomic hybridisation was used to compare the
mitoxantrone-resistant cell line with its sensitive parental line
GLC4. In addition, we also compared both cell lines with a normal
DNA sample (genomic DNA isolated from peripheral blood
lymphocytes from a healthy person). Results of all CGH
experiments are shown in Figure 1. The CGH results of GLC4-
MITO vs GLC4 are summarized in Table 2. Loss (17x) of
chromosomal material was more frequent than gain (8x) in
GLC4-MITO compared to GLC4. Relative to GLC4 no high level
amplifications could be detected in GLC4-MITO using CGH. We
detected loss of 3p (containing the topoisomerase IIb gene) and
17q (containing the topoisomerase IIa gene) in GLC4-MITO
providing a plausible explanation for the previously identified
reduction of topoisomerase activity (Withoff et al, 1996).
The genomic areas enriched in GCL4-MITO as compared with
GLC4 were screened in a database for the presence of known drug
resistance-related transporter genes (Mu ¨ller M (2001) Transporters
in the Liver and ATPbinding Casette (ABC)-Proteins October 2002.
Internet communication, http://nutrigene.4t.com/humanabc.htm).
We identified seven known transporter genes: ABCB6 (ABCB6)
(Allikmets et al, 1996), ABCB2 (TAP1), ABCB3 (TAP2) (Bahram
et al, 1991), ABCC10 (MRP7) (Hopper et al, 2001), ABCF1 (ABC50)
(Richard et al, 1998), ABCA2 (ABC2) (Vulevic et al, 2001) and
ABCC4 (MRP4) (Kool et al, 1997) (see Table 3).
These transporter genes located at 2q, 6p, 9q and 13q,
respectively, were analysed for overexpression at the RNA and/or
protein level. ABCB2 and ABCB3 protein expression was screened
by immunocytochemistry. Staining with the anti-ABCB2 antibody
revealed a comparable, weakly positive, cytoplasmatic staining in
GLC4 and GLC4-MITO. With the anti-ABCB3 antibody, a
moderate to strong cytoplasmatic staining pattern was observed
with no differences between both cell lines. Reverse transcriptase–
polymerase chain reactions were performed for the other four
transporter genes, for the BCRP1 gene (known to be involved in
mitoxantrone resistance) and for MRP1, MRP2 and MRP5 as
controls. Densitometric scanning of the PCR reaction product
bands revealed similar expression levels for ABCB6, ABCF1,
ABCC10, ABCC4, MRP1 and MRP5 in the parental cell line GLC4
as compared with resistant line GLC4-MITO. MRP2 was slightly
higher in GLC4-MITO, but FACS results showed no difference in
Table 1 Primer sequences and PCR conditions for the ATP-binding cassette transporter (ABC) genes that were located in the amplified chromosomal
regions, BCRP1, MRP1, MRP2, MRP5 and the control genes hypoxanthine phosphoribosyltransferase (HPRT) and b-2 microglobulin, used for DNA
amplification in the RT–PCR
Gene Sense primer (50-30) Antisense primer (30-50) Temperature (1C)
Cycles
(n)
Product size
(base pairs)
ABCB6 GGG CCG TAT TGA GTT TGA GA ATG TCC TGC CCA TCT ATT CG 95, 55, 72
a 26 201
ABCC10 (MRP7) CTC CCA CTG GAT CTC TCA GC TCG CAT ACA CGG TGA GGT AG 95, 57, 72
a 30 200
ABCF1 (ABC50) GGA GTA CAC TGT GCG CTT CA TCA GCA GCA GGA GTA GCG TA 95, 55, 72
a 26 196
ABCA2 (ABC2) GAG ATC CGC AGA GAG ATG GA CTT CAG GAT GAG GTC CCA GA 95, 57, 72
a 30 207
ABCC4 (MRP4) AAT ACC CTT GGT TCC CCT TGG ATC CTG GTG TGC ATC AAA CA 95, 55, 72
a 32 202
ABCG2 (BCRP1) CAG AGA TCA TAG AGC CTT CC ACA CTC TGT AGT ATC CTC TG 95, 55, 72
a 32 453
ABCC1(MRP1) AAT GCG CCA AGA CTA GGA AG ACC GGA GGA TGT TGA ACA AG 95, 56, 72
a 29 990
ABCC2 (MRP2) CTG GTT GAT GAA GGC TCT GT CTG CCA TAA TGT CCA GGT TC 95, 58, 72
a 31 1067
ABCC5 (MRP5) GGA TAA CTT CTC AGT GGG GGA ATG GCA ATG CTC TAA AG 95, 55, 72
a 29 380
HPRT CGT GGG GTC CTT TTC ACC AGC AAG AAT TAT GGA CAG GAC TGA ACG TC 95, 55, 72
a 27 380
b-2 microglobulin CCA GCA GAG AAT GGA AAG TC GAT GCT GCT TAC ATG TCT CG 95, 55, 72
a 20 268
aFor denaturation (3000), annealing (3000), extension (3000).
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sthe effect of MRP inhibitor MK-571 on GLC4 and GLC4-MITO.
Reverse transcriptase–polymerase chain reaction revealed a lower
mRNA level of BCRP1 in GLC4-MITO compared with GLC4 cell
line(see Figure 2). However, the ABCA2 transporter showed a
stronger signal in GLC4-MITO as compared to GLC4 indicating an
increased expression level. Densitometric scanning of the PCR
reaction product bands revealed a two-fold higher signal of
GLC4-MITO (GLC4-MITO/HPRT: (n¼3, ratio¼2.8470.17) com-
pared to the GLC4 (GLC4/HPRT: (n¼3, ratio¼1.4470.04)
signal using the housekeeping gene HPRT as a loading control
(triplicate experiments).
ABCA2 was shown by Laing et al (1998) to confer resistance to
estramustine in an ovarian cancer cell line. In order to
demonstrate functionality of ABCA2 in GLC4-MITO, a cytotoxicity
assay with estramustine in GLC4-MITO, GLC4-ADR and GLC4 was
performed. Figure 3 shows the result of the cytotoxity assay. A 1.5-
and 2.0-fold higher drug concentration was needed to obtain the
IC70 and IC90, respectively, in GLC4-MITO compared to GLC4. The
GLC4-MITO vs GLC4
GLC4-MITO vs GLC4 normal DNA
GLC4 vs normal DNA
Explanation CGH profile
1−23 2−24 3−23 4−25
6−23 8−24 9−22 10−24 11−25 12−24
13−25 14−22 15−26 16−26 17−26 18−26
20−25 X−13 Y−13
1−21 2−19 3−21
6−21 7−23 8−23 9−46
4−22 5−22
10−19 11−23 12−24
13−24 14−23 15−20 16−24 17−24 18−24
19−23 20−23 21−24 22−24 X−9Y −12
22−25 21−26 19−25
7−24
5−24 1−25 2−21 3−23 4−25 5−24
6−24 7−22 8−25 9−24 10−24 11−24 12−25
18−25 17−24 16−24 15−25 14−26 13−23
19−23
6−23
20−24 21−24 22−24 X−13 Y−13
profile +mean +ratio, loss =0.85, gain =1.15 profile +mean +ratio, loss =0.85, gain =1.15
profile +mean +ratio, loss =0.85, gain =1.15
Ratio test/reference DNA
Loss borderline 0.085
Gain bar
Gain borderline 1.15
Loss bar
Number of chromosomes analysed
Chromosome number
A B
C D
Figure 1 Comparative genomic hybridisation profiles of GLC4-MITO vs GLC4 and normal control DNA. (A) CGH profile of GLC4-MITO vs GLC4 (blue
line) (B) CGH profile of GLC4 vs normal male DNA. (C) CGH profile of GLC4-MITO vs normal male DNA. (D) Explanation of schematic representation
of a CGH profile gain 41.15(green bar) loss o0.85 (red bar).
Table 2 Copy number changes detected by CGH in GLC4-MITO vs GLC4
Gain
rev ish enh(2q34 6p25q14 9q34 13q21q34 14q32 15q24q26 19q10q13.1 Xp)
Loss
rev ish dim(1p36.3p34.1 2q37 3p36p22 3q11.2q23 3q25q29 4q13q28 6q22q24 6q26q27 8q22q23 8q24.2q24.3 11p15p14 11p12 16p 17q12q25 18p11 20p13p11.2 Xq)
CGH¼comparative genomic hybridisation.
New efflux pump in mitoxantrone-resistant GLC4 cells
R Boonstra et al
2414
British Journal of Cancer (2004) 90(12), 2411–2417 & 2004 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sGLC4-ADR cell line with increased MRP1 and LRP expression (but
no reduced mitoxantrone accumulation) was more sensitive to
estramustine than the GLC4 and GLC4-MITO cell line. A 2.5-fold
lower drug concentration was needed to obtain the IC90 compared
to GLC4 (see Figure 3).
The ability of tumour cell lines GLC4 and GLC4-MITO to
extrude mitoxantrone, and the effect of estramustine on mitoxan-
trone accumulation were measured with a FACS assay. The
mitoxantrone accumulation after exposure to 3mM mitoxantrone
was 25% reduced in GLC4-MITO (76711 MFI, P¼0.03) compared
to GLC4 (set as 100) (see Figure 4). When 10 and 25mM
estramustine were added during incubation with mitoxantrone,
the mitoxantrone accumulation in GLC4-MITO increased to
85710 MFI (n¼3, P¼0.004) with 10mM estramustine and to
106715 MFI (n¼3, P¼0.03) with 25mM estramustine. However,
mitoxantrone accumulation was not effected in GLC4, 10175 MFI
(n¼3, P¼0.41) and 107711 MFI (n¼3, P¼0.16) with 10 or
25mM estramustine (see Figure 4). When 25mM estramustine was
added to GLC4-MITO, the cellular mitoxantrone level increased to
the same level as for GLC4 (see Figure 4). The BCRP1 (FTC), P-gp
(PSC833) and MRPs (MK-571) inhibitors were added to GLC4-
MITO and GLC4 prior to addition of 3mM mitoxantrone, and the
drug accumulation was measured by FACS analysis. The
mitoxantrone accumulation expressed as MFI was set to 100 with
addition of only 3mM mitoxantrone. The addition of the P-gp
inhibitor PSC833 caused an increase in mitoxantrone accumula-
tion to 113719 (n¼3, P¼0.17) in GLC4 and an increase to
114720 (n¼3 P¼0.19) in GLC4-MITO. When the inhibitor for
BCRP1, FTC was added, a mitoxantrone increase was detected in
GLC4 (114710 (n¼3 P¼0.07)) and GLC4-MITO (12878(n¼3,
P¼0.02)). However, there was no significant difference (P¼0.13)
in mitoxantrone accumulation between the cell lines. The addition
of the MRP inhibitor MK-571 caused an increase in mitoxantrone
accumulation to 117727 in GLC4 (n¼3, P¼0.09) and to 119728
(n¼3, P¼0.22) in GLC4-MITO.
DISCUSSION
This study shows that with CGH it was possible to define
an amplified chromosomal area, in which after a database
search ABCA2 could be identified as a candidate gene involved
in mitoxantrone resistance. In the mitoxantrone-resistant
GLC4-MITO, mechanisms underlying the mitoxantrone accumula-
tion defect were unknown (Withoff et al, 1996). Direct compa-
rison with CGH of GLC4-MITO and its parental cell line GLC4
resulted in a simplified overview of numerical differences (see
Table 2). These differences fitted in the complex karytotype
obtained with cytogenetics. Although in both lines marker
chromosomes were found, which made it difficult to identify
chromosomal gains.
Mitoxantrone resistance in GLC4-MITO is at least partly due
to the absence or low-level expression of topoisomerase IIa and
b compared with its parental line (Withoff et al, 1996). The loss of
3p (containing the topoisomerase IIb gene) and 17q (containing
the topoisomerase IIa gene) in GLC4-MITO detected with CGH is
in accordance with this previously found reduction of topoisome-
rase activity (Withoff et al, 1996).
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Figure 2 RT–PCR of selected efflux pump genes. (A, B): Expression of MRP1 MRP2 MRP5 BCRP b -2 microglobulin and HRTP mRNA in the
mitoxantrone-resistant cell line GLC4-MITO and sensitive cell line GLC4. (C): Expression of ABCB6 ABCF1 ABCC10 ABCC4 ABCA2 b 2-microglobulin
and HRTP in the mitoxantrone-resistant cell line GLC4-MITO and its sensitive parent line GLC4.
Table 3 Transporter genes located in gained chromosomal areas when
GLC4-MITO was compared with GLC4 using CGH
Name (symbol) Chromosomal location References
ABCB6 (ABCB6) 2q33–q36 Allikmets et al (1996)
ABCB2 (TAP1) 6p21.3 Bahram et al (1991)
ABCB3 (TAP2) 6p21.3 Bahram et al (1991)
ABCC10 (MRP7) 6p21 Hopper et al (2001)
ABCF1 (ABC50) 6p21.33 Richard et al (1998)
ABCA2 (ABC2) 9q34 Vulevic et al (2001)
ABCC4 (MRP4) 13q32 Kool et al (1997)
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Figure 3 Representative cytotoxity profile of the estramustine sensitiv-
ities of GLC4-MITO (’), GLC4-ADR (&) and GLC4 () measured with an
MTA. Values represent the means of four experiments7s.d.
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which might be completely due to lowered topoisomerase II levels
(Withoff et al, 1996). This implies that an uncharacterised
transporter protein capable of reducing mitoxantrone accumula-
tion without a role in doxorubicin resistance is involved in
mitoxantrone resistance in GLC4-MITO.
Mitoxantrone resistance has been contributed to overexpression
of various ABC transporters. The BCRP1 half-transporter protein
was found to be responsible for mitoxantrone resistance (Doyle
et al, 1998; Miyake et al, 1999; Ross et al, 1999; Litman et al, 2000).
Scheffer et al (2000) had already shown that there was no BCRP1
overexpression in GLC4-MITO using BXP-34 antibody. Compara-
tive genomic hybridisation analysis in the present study revealed
the loss of the 4q13–q28 region harbouring BCRP1 (4q21–22,
Knutsen et al, 2000) in GLC4-MITO and a lower BCRP1 mRNA
expression compared with GLC4 (Figure 2A). Thus, BCRP1 is not
involved in mitoxantrone resistance in GLC4-MITO. ABCB2 and
ABCB3 have been associated with mitoxantrone resistance in a
gastric carcinoma cell line (Lage et al, 2001). Mitoxantrone
resistance due to a reduced expression of topoisomerase II and
an unknown efflux pump was observed in human (Hazlehurst et al,
1999; Diah et al, 2001) and mouse (Nielsen et al, 2000) cell lines. In
the present study, several genomic regions that harbour candidate
drug resistance genes in the GLC4-MITO were located. In these
regions, seven transporter genes were identified (Mu ¨ller M (2001)
Transporters in the Liver and ATPbinding Casette (ABC)-Proteins
October 2002. Internet communication, http://nutrigene.4t.com/
humanabc.htm). Reverse transcriptase–polymerase chain reaction
for four transporter genes, ABCB6 (Allikmets et al, 1996), ABCF1
(Richard et al, 1998), ABCC4 (Kool et al, 1997) and ABCC10
(Hopper et al, 2001), and immunohistochemistry of two genes,
ABCB2 and ABCB3 (Bahram et al, 1991), showed similar levels of
mRNA and protein, respectively, in GLC4-MITO and GLC4.
However, the ABCA2 (Vulevic et al, 2001) gene located on 9q34
showed an increased mRNA expression in GLC4-MITO compared
with GLC4. No causal link between ABCA2 and mitoxantrone
resistance has been demonstrated. Gain of 9q34, including the
ABCA2 transporter gene and overexpression of ABCA2 mRNA in
an ovarian carcinoma cell line has been associated with enhanced
efflux of estramustine (Laing et al, 1998). Transfection of ABCA2 in
HEK293 cells resulted in a two-fold resistance to estramustine
compared to normal HEK293 cells (Vulevic et al, 2001). ABCA2 has
been suggested to play a role in the transport of steroids, lipids and
related molecules (Vulevic et al, 2001; Zhou et al, 2001) and is
expressed at high level in brain and neural tissue (The cancer
genome anatomy project (2001): Sage Genie, Sage Anatomic
Viewer, Digital Northern for ABCA2. Internet communication,
http://cgap.nci.nih.gov/SAGE/AnatomicViewer). ABCA2 expression
has been observed in tumour cell lines of different origin and
intracellular localisation to the endosome/lysosome compartment
was demonstrated (Vulevic et al, 2001). Lysosomes were capable of
exocytosis in response to extracellular stimuli also in nonsecretory
cells (Jaiswal et al, 2002). In the GLC4 and the GLC4-ADR cell
lines, the transport of doxorubicin by secretory vesiscles with
MRP1containing membranes was previously demonstrated (van
Luyn et al, 1998). In GLC4-MITO (and GLC4), mitoxantrone
extrusion could take place analogously by the lysosome exocytosis
pathway.
Analysis of the cytotoxicity of estramustine on GLC4, GLC4-
MITO and GLC4-ADR showed a two-fold resistance in GLC4-
MITO (see Figure 3) comparable with the estramustine resistance
found in an ABCA2-transfected cell line (Vulevic et al, 2001).
Remarkably, the multidrug-resistant, MRP1-overexpressing GLC4-
ADR (Versantvoort et al, 1995; Withoff et al, 1996) was more
sensitive to estramustine than the GLC4 control cell line (see
Figure 3). In GLC4-MITO, addition of 25mM estramustine
increased mitoxantrone accumulation to the level of GLC4 (see
Figure 4), suggesting that estramustine is able to block mitoxan-
trone efflux in GLC4-MITO. This effect of estramustine is unlikely
to be due to P-gp (Speicher et al, 1994; Smith et al, 1995) or MRP5
(Wielinga et al, 2003) of which estramustine has been shown to
modulate the transport activity. In the present model, no P-gp
overexpression and no (selective) effect of the P-gp blocker
PSC833 on mitoxantrone accumulation were found. In GLC4-
MITO, no increased mRNA expression was found for MRP5 or one
of the other multidrug-resistance related transporters tested.
Mitoxantrone accumulation with specific inhibitors of P-gp, MRPs
and BCRP1 revealed an a-selective and (except for FTC) not
significant increase in mitoxantrone accumulation in GLC4 as well
as in GLC4-MITO.
Our data provide genetic and biochemical support for
the concept that ABCA2 expression is a plausible contributory
factor to the multifactorial mitoxantrone-resistant phenotype,
while for other transporters no apparent changes in the expres-
sion could be correlated with mitoxantrone accumulation or
cytotoxicity.
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